

CURRICULUM VITAE

Jonathan William Agins, MD

Precision Trials
3815 East Bell Road, Suite 4500
Phoenix, AZ 85032
602-931-4507

Education:

1986 – 1991 SUNY
Albany, NY
Bachelor of Arts

1991 – 1995 SUNY
Brooklyn, NY
Doctor of Medicine

**Postgraduate
Training:**

1995 – 2001 SUNY
Brooklyn, NY
Urology Residency

**Professional
Experience:**

2009 – Present Investigator
Precision Trials
Phoenix, AZ

2006 – Present Urologist
Valley Urologic Associates
Phoenix, AZ

2006 – Present Urologist
Valley Urologic Associates
Goodyear, AZ

2006 – Present Urologist
Valley Urologic Associates
Glendale, AZ

Curriculum Vitae
Jonathan W. Agins, MD
Page 2

2003 – 2006 Associate Urologist
 John D. Siegel, MD
 Millburn, NJ

2001 – 2003 Associate Urologist
 Bay Ridge Urology Associates
 Brooklyn, NY

Professional
Memberships:

Diplomat, American Board of Urology
Member, American urologic Association
Member, Western Section of American Urologic Association
Chairman, Physician Leadership Council, Arrowhead Hospital, Glendale, AZ
Member, Credentials Committee, Arrowhead Hospital, Glendale, AZ
Vice Chief of Surgery, Arrowhead Hospital, Glendale, AZ
Consultant, Arizona Medical Board, Scottsdale, AZ

Licenses/Certifications:

AZ #35346

Publications:

- 1 “The Prognostic Significance of Atypia in Needle Biopsy of Prostate”, presented at FG Valentine Essay Contest, New York Academy of Medicine, March 1998
- 2 Mydlo JH, **Agins JW**, Donohoe J, Grob BM. A Review of Urologic Cancer Patients with Multiple Primary Malignancies. World J Urol. 2001 Aug;19(4):240-3.

Trainer and Consultant
Medtronic, Inc.

Trainer and Consultant
American Medical Systems, Inc.

Trainer and Consultant
Allergan USA, Inc.

Research Experience:

Investigator: Phase IV Clinical Trial
Safety and Efficacy of Vardenafil
Bayer Pharmaceuticals, 2003-2005

Investigator: Nutritional Aspects of Prostate Cancer Prevention
Memorial Sloan-Kettering Cancer Center, 1999-2001

Investigator: Effect of Surgeon's Experience on Outcome of Radical
Retropubic Prostatectomy
Memorial Sloan-Kettering Cancer Center, 1999-2000

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of XXXXX Followed by a Treatment with XXXXX as Applicable in Patients with Idiopathic Overactive Bladder with Urinary Incontinence

A Multicenter, Long-term Follow-up Study of the Safety and Efficacy of XXXXX in Patients with Idiopathic Overactive Bladder with Urinary Incontinence

A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF XXXXX FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS).

A Multicenter, Randomized Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose XXXXX as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer.

Prospective, Multicenter, Randomized, Parallel-Group Trial Comparing the Safety and Efficacy of XXXXX Therapy to Standard Medical Therapy for Subjects With Urinary Urge Incontinent Symptoms of Overactive Bladder (InSite UI)

Prospective, Multicenter, Randomized, Parallel-Group Trial Comparing the Safety and Efficacy of XXXXX Therapy to Standard Medical Therapy for Subjects With Urgency-Frequency Symptoms of Overactive Bladder (Insite UF)